Literature DB >> 28122315

Intrauterine insemination-No more Mr. N.I.C.E. guy?

Minna E Geisler1, Mark Ledwidge2, Margaret Bermingham2, Mary McAuliffe3, Moya B McMenamin3, John J Waterstone3.   

Abstract

OBJECTIVE: To determine the per cycle chance of a live birth and to identify factors that may support a more individualised application of IUI in view of National Institute for Health and Care Excellence (NICE) updated guideline on fertility 2013. STUDY
DESIGN: A retrospective, cohort study of 851 couples (1688 cycles) with unexplained, mild endometriosis, one patent Fallopian tube (with ovulation occurring in the corresponding ovary), mild male factor or ovulatory dysfunction, who initiated their first cycle of IUI/COH during the study period 2009-2013 and completed up to 3 cycles. Exclusion criteria included donor sperm and diminished ovarian reserve. Success factors and probabilities were determined based on live birth rates.
RESULTS: Mean age was 33.8±3.3years and mean duration of subfertility was 2.28±1.47years. Independent associates of successful outcome factors were lower age (AOR 0.93; 95%CI 0.89-0.98, p=0.007) and multiparity (AOR 1.72; 95%CI 1.17-2.52). Live-birth rates declined independently of other factors from 15.3% (n=130/851) in cycle 1-7.0% (n=19/273) in cycle 3 (AOR 0.76; 95%CI, 0.62-0.93, p=0.008). Per cycle probabilities of live birth ranged from 21.4% to 5.1% dependent on age, cycle number and previous parity. The unadjusted cumulative pregnancy rate for live birth per cycle started, over three cycles, was 34.9% with a multiple live birth rate per cycle started of 5.4%. The associates of live birth amongst those with unexplained sub-fertility only (n=632, first cycle attempt) were also analysed, yielding similar results.
CONCLUSIONS: IUI/COH is a simple treatment that produces good live birth rates, especially in younger patients and/or those with previous parity. More than 90% of total live births with IUI/COH is achieved during the first two cycles. As a retrospective, observational study, there is no comparator group and therefore we cannot comment on the relative efficacy of up to three IUI cycles over expectant management in a similar cohort. Our study suggests that probabilities of success can be used to individualise treatment decisions and that there is merit in continuing to offer IUI before resorting to IVF for certain patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Intrauterine insemination; Unexplained subfertility

Mesh:

Year:  2017        PMID: 28122315     DOI: 10.1016/j.ejogrb.2017.01.016

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

1.  Intrauterine insemination cycles: prediction of success and thresholds for poor prognosis and futile care.

Authors:  Alessandra J Ainsworth; Emily P Barnard; Sarah C Baumgarten; Amy L Weaver; Zaraq Khan
Journal:  J Assist Reprod Genet       Date:  2020-08-15       Impact factor: 3.412

2.  Correlation between the wide range of tubal pathology discovered by routine hysterosalpingography in a university hospital in Romania and the successful pregnancy rate. A cohort study.

Authors:  R Covali
Journal:  J Med Life       Date:  2017 Oct-Dec

3.  Prognostic factors in intrauterine insemination cycles.

Authors:  Fernanda Sicchieri; Aline Bomfim Silva; Ana Carolina Japur de Sá Rosa E Silva; Paula Andrea de Albuquerque Sales Navarro; Rui Alberto Ferriani; Rosana Maria Dos Reis
Journal:  JBRA Assist Reprod       Date:  2018-03-01

4.  Intrauterine insemination as a primary viable option to infertile couples: evaluation of patients in a private center.

Authors:  Marília Porto Bonow; Ricardo Ditzel Delle Donne; Vinicius Bonato da Rosa; José Augusto Lucca; Cristian Maio Hillesheim; Alessandro Schuffner
Journal:  JBRA Assist Reprod       Date:  2019-10-14

5.  Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles.

Authors:  Gulam Bahadur; Roy Homburg; Judith E Bosmans; Judith A F Huirne; Peter Hinstridge; Kanna Jayaprakasan; Paul Racich; Rakib Alam; Ioannis Karapanos; Afeeza Illahibuccus; Ansam Al-Habib; Eric Jauniaux
Journal:  BMJ Open       Date:  2020-03-16       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.